Ustekinumab biosimilar(Rani Therapeutics)

乌司奴单抗生物类似药(Rani Therapeutics)

Report date: 2023/09/19 14:59:11

Base Information

Drug NameUstekinumab biosimilar(Rani Therapeutics)
Drug Alias NameUstekinumab biosimilar(Rani Therapeutics)RaniPillRT-111
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionInterleukin-12 inhibitorsInterleukin-23 inhibitors
TargetsInterleukin-12Interleukin-23
Therapy Area/IndicationsPsoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesRani Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesRani Therapeutics LlcRani Therapeutics Holdings Inc
Inactive CompaniesN/A
Active IndicationsPsoriasis
Inactive IndicationsN/A

Other Information

ATC CodeL04AC05
Related LinksN/A